Stock Market Reviews

CASI (CASI Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on CASI (CASI Pharmaceuticals, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
  SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 23, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for ...
  Dec 23, 2025 - $CASI
• CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing
  - Investment to Fund Phase 1 Study in Renal Allograft Antibody-Mediated Rejection (AMR) in China SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 11, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI, the "Company"), a clinical-stage biopharmaceutical ...
  Dec 11, 2025 - $CASI
• CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting
  SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 8, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company developing CID-103, a potentially best-in-class, anti-CD38 monoclonal antibody, for patients ...
  Dec 8, 2025 - $CASI
• CASI Pharmaceuticals Announces Changes in Board Governance
  James Huang appointed as Non-Executive Chairman of CASI Board of Directors SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 19, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing ...
  Nov 19, 2025 - $CASI
• CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
  SOUTH SAN FRANCISCO, CA / ACCESS Newswire / November 14, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on the development of CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for ...
  Nov 14, 2025 - $CASI
• CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
  SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 10, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for ...
  Nov 10, 2025 - $CASI
• CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
  SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 4, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for ...
  Nov 4, 2025 - $CASI
• CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting
  - CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody- Phase 1 dose escalation study in Immune Thrombocytopenia (ITP) results and update SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 3, 2025 / CASI Pharmaceuticals, Inc. ...
  Nov 3, 2025 - $CASI
• CASI Pharmaceuticals Appoints James Huang to Board of Directors
  - Industry veteran brings over 35 years of biotech experience as a successful entrepreneur and investor- Operating experience to significantly enhance development program of CID-103 (anti-CD38 mAb) SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September ...
  Sep 26, 2025 - $CASI
• CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study
  - CID-103 is a potential best-in-class, clinical stage anti-CD38 monoclonal antibody - Safety profile observed in first four dose cohorts supports continued development - No serious adverse events or dose-limiting toxicities have been reported SOUTH ...
  Sep 8, 2025 - $CASI